![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
School of Public Health/Environmental and Occupational Health Sciences Institute (S.-L.W., X.-Y.H., J.-Y.H.), University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and School of Public Health, Nanjing Medical University, Nanjing, People's Republic of China (S.-L.W.)
Cytochrome P450 (P450) enzymes play a critical role in the metabolic activation of a wide variety of environmental carcinogens. Recently, a novel human P450 enzyme, CYP2S1, has been identified. It is inducible by dioxin and other classical aryl hydrocarbon receptor ligands. However, little is known regarding the substrates and the functional role of CYP2S1. Since CYP2S1 is predominantly expressed in human lung and trachea, it is reasonable to speculate that CYP2S1 may play an important role in metabolizing the environmental chemicals to which human respiratory tissues are exposed. In the present study, we examined the activity of human CYP2S1 in the metabolism of nicotine and in the activation of three potent carcinogens in cigarette smoke, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), benzo[a]pyrene (BaP), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). The full-length CYP2S1 cDNA was amplified by nested polymerase chain reaction from a human lung cDNA library and was expressed in both Chinese hamster ovary (CHO) cells and Sf9 insect cells. In contrast to the positive controls, i.e., CHO cells expressing human CYP2A13 (for NNK activation) or human CYP1A1 (for BaP activation), there was no increase in NNK- or BaP-induced toxicity in the CHO cells expressing CYP2S1. The heterologously expressed CYP2S1 proteins showed no detectable activity in metabolizing nicotine and PhIP. These results clearly demonstrate that CYP2S1 does not catalyze the metabolism of nicotine and the metabolic activation of these lung carcinogens.
This article has been cited by other articles:
![]() |
P. H. Bui and O. Hankinson Functional Characterization of Human Cytochrome P450 2S1 Using a Synthetic Gene-Expressed Protein in Escherichia coli Mol. Pharmacol., November 1, 2009; 76(5): 1031 - 1043. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-L. Wang, J.-F. Han, X.-Y. He, X.-R. Wang, and J.-Y. Hong Genetic Variation of Human Cytochrome P450 Reductase as a Potential Biomarker for Mitomycin C-Induced Cytotoxicity Drug Metab. Dispos., January 1, 2007; 35(1): 176 - 179. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-L. Wang, X.-Y. He, J. Shen, J.-S. Wang, and J.-Y. Hong The Missense Genetic Polymorphisms of Human CYP2A13: Functional Significance in Carcinogen Activation and Identification of A Null Allelic Variant Toxicol. Sci., November 1, 2006; 94(1): 38 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-R. Zhu, P. E. Thomas, G. Lu, K. R. Reuhl, G.-Y. Yang, L.-D. Wang, S.-L. Wang, C. S. Yang, X.-Y. He, and J.-Y. Hong CYP2A13 in Human Respiratory Tissues and Lung Cancers: An Immunohistochemical Study with A New Peptide-Specific Antibody Drug Metab. Dispos., October 1, 2006; 34(10): 1672 - 1676. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-L. Wu, C. D. Sohl, T. Shimada, and F. P. Guengerich Recombinant Enzymes Overexpressed in Bacteria Show Broad Catalytic Specificity of Human Cytochrome P450 2W1 and Limited Activity of Human Cytochrome P450 2S1 Mol. Pharmacol., June 1, 2006; 69(6): 2007 - 2014. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-F. Han, S.-L. Wang, X.-Y. He, C.-Y. Liu, and J.-Y. Hong Effect of Genetic Variation on Human Cytochrome P450 Reductase-Mediated Paraquat Cytotoxicity Toxicol. Sci., May 1, 2006; 91(1): 42 - 48. [Abstract] [Full Text] [PDF] |
||||